Hydroxymethylnitrofurazone lymphatic uptake with nanostructured lipid carrier after oral administration in rats

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Leishmaniasis Infographic. WHO. Geneva, Switzerland (2021).
  Google Scholar
• 2. Organização Panamericana da Saúde-Organização Mundial da Saúde. Leishmanioses: Informe Epidemiológico das Américas (2016).
  Google Scholar
• 3. Chappuis F, Sundar S, Hailu A et al. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat. Rev. Microbiol. 5(11), S7–S16 (2007).
  CASGoogle Scholar
• 4. Moore JE Jr, Bertram CD. Lymphatic system flows. Annu. Rev. Fluid Mech. 50, 459–482 (2018).
  MedlineGoogle Scholar
• 5. Khan AA, Mudassir J, Mohtar N, Darwis Y. Advanced drug delivery to the lymphatic system: lipid-based nanoformulations. Int. J. Nanomed. 8, 2733–2744 (2013).
  MedlineGoogle Scholar
• 6. Trevaskis NL, Kaminskas LM, Porter CJH. From sewer to saviour – targeting the lymphatic system to promote drug exposure and activity. Nat. Rev. Drug Discov. 14(11), 781–803 (2015).
  Medline CASGoogle Scholar
• 7. Yousef M, Silva DA, Bou-Chacra NA, Davies NM, Löbenberg R. The lymphatic system: a sometimes-forgotten compartment in pharmaceutical science. J. Pharm. Pharm. Sci. 24, 533–547 (2021).
  Medline CASGoogle Scholar
• 8. Chaudhary S, Garg T, Murthy RSR, Rath G, Goyal AK. Recent approaches of lipid-based delivery system for lymphatic targeting via oral route. J. Drug Target. 22(10), 871–882 (2014).
  Medline CASGoogle Scholar
• 9. Shete H, Chatterjee S, De A, Patravale V. Long chain lipid based tamoxifen NLC. Part II: pharmacokinetic, biodistribution and in vitro anticancer efficacy studies. Int. J. Pharm. 454(1), 584–592 (2013).
  Medline CASGoogle Scholar
• 10. Khan S, Shaharyar M, Fazil M, Hassan MQ, Baboota S, Ali J. Tacrolimus-loaded nanostructured lipid carriers for oral delivery – in vivo bioavailability enhancement. Eur. J. Pharm. Biopharm. 109, 149–157 (2016).
  Medline CASGoogle Scholar
• 11. Chaudhary S, Garg T, Murthy RSR, Rath G, Goyal AK. Development, optimization and evaluation of long chain nanolipid carrier for hepatic delivery of silymarin through lymphatic transport pathway. Int. J. Pharm. 485(1–2), 108–121 (2015).
  Medline CASGoogle Scholar
• 12. Patel P, Patel M. Enhanced oral bioavailability of nintedanib esylate with nanostructured lipid carriers by lymphatic targeting: in vitro, cell line and in vivo evaluation. Eur. J. Pharm. Sci. 159, 105715 (2021).
  Medline CASGoogle Scholar
• 13. Poonia N, Kharb R, Lather V, Pandita D. Nanostructured lipid carriers: versatile oral delivery vehicle. Future Sci. OA 2(3), FSO135 (2016).
  MedlineGoogle Scholar
• 14. Mennini N, Cirri M, Maestrelli F, Mura P. Comparison of liposomal and NLC (nanostructured lipid carrier) formulations for improving the transdermal delivery of oxaprozin: effect of cyclodextrin complexation. Int. J. Pharm. 515(1–2), 684–691 (2016).
  Medline CASGoogle Scholar
• 15. Chung MC, Carvalho Güido RV, Favarato Martinelli T et al. Synthesis and in vitro evaluation of potential antichagasic hydroxymethylnitrofurazone (NFOH-121): a new nitrofurazone prodrug. Bioorg. Med. Chem. 11(22), 4779–4783 (2003). • Describes the first-time synthesis of hydroxymethylnitrofurazone (NFOH).
  Medline CASGoogle Scholar
• 16. Monteiro LM, Löbenberg R, Ferreira EI et al. Targeting Leishmania amazonensis amastigotes through macrophage internalisation of a hydroxymethylnitrofurazone nanostructured polymeric system. Int. J. Antimicrob. Agents 50(1), 88–92 (2017). •• Demonstrates the antileishmania activity of NFOH.
  Medline CASGoogle Scholar
• 17. Serafim EOP, De Albuquerque E Silva AT, De Haro Moreno A et al. Pharmacokinetics of hydroxymethylnitrofurazone, a promising new prodrug for Chagas' disease treatment. Antimicrob. Agents Chemother. 57(12), 6106–6109 (2013). •• Describe the pharmacokinetics of NFOH.
  Medline CASGoogle Scholar
• 18. de Souza A, Yukuyama MN, Barbosa EJ et al. A new medium-throughput screening design approach for the development of hydroxymethylnitrofurazone (NFOH) nanostructured lipid carrier for treating leishmaniasis. Colloids Surf. B Biointerfaces 193, 111097 (2020). •• Describes the preparation of nanostructured lipid carrier loaded with hydroxymethylnitrofurazone used in the present study.
  Medline CASGoogle Scholar
• 19. Monteiro LM, Löbenberg R, Cotrim PC, Lima G, De Araujo B, Bou-Chacra N. Buparvaquone nanostructured lipid carrier: development of an affordable delivery system for the treatment of leishmaniases. Biomed. Res. Int. 2017, 1–11 (2017).
  Google Scholar
• 20. Fu Q, Sun J, Ai X et al. Nimodipine nanocrystals for oral bioavailability improvement: role of mesenteric lymph transport in the oral absorption. Int. J. Pharm. 448(1), 290–297 (2013).
  Medline CASGoogle Scholar
• 21. Monteiro LM, Tavares GD, Ferreira EI, Consiglieri VO, Bou-Chacra NA, Löbenberg R. Reverse phase high-performance liquid chromatography for quantification of hydroxymethylnitrofurazone in polymeric nanoparticles. Brazilian J. Pharm. Sci. 51(3), 561–568 (2015).
  CASGoogle Scholar
• 22. de Souza A, de Almeida MKL, Barbosa JA et al. Development of an HPLC method for identification and quantification of anti-leishmaniasis drug candidate NFOH after oral administration of NLC-NFOH in rats. Chem. Africa 6(2), 837–843 (2023). • Describes the high-performance liquid chromatography methodology to quantify NFOH in rats' serum.
  CASGoogle Scholar
• 23. Zhu Q, Chen Z, Paul PK, Lu Y, Wu W, Qi J. Oral delivery of proteins and peptides: challenges, status quo and future perspectives. Acta Pharm. Sin. B 11(8), 2416–2448 (2021).
  Medline CASGoogle Scholar
• 24. Herman TF, Santos C. First pass effect. StatPearl (Internet), StatPearls Publishing (2023). www.ncbi.nlm.nih.gov/books/NBK551679/
  Google Scholar
• 25. Chavda H, Singh Anand I. Biopharmaceutics classification system. Syst. Rev. Pharm. 1(1), 62–69 (2010).
  CASGoogle Scholar
• 26. Zhang Z, Lu Y, Qi J, Wu W. An update on oral drug delivery via intestinal lymphatic transport. Acta Pharm. Sin. B 11(8), 2449–2468 (2021).
  Medline CASGoogle Scholar
• 27. Jitta SR, Salwa, Bhaskaran NA et al. Enhanced tissue distribution of ritonavir-loaded nanostructured lipid carriers – recommending its dose reduction. Drug Deliv. Transl. Res. 14, 116–130 (2023).
  MedlineGoogle Scholar
• 28. Jitta SR, Bhaskaran NA, Salwa, Kumar L. Anti-oxidant containing nanostructured lipid carriers of ritonavir: development, optimization, and in vitro and in vivo evaluations. AAPS PharmSciTech 23(4), 116–130 (2022).
  MedlineGoogle Scholar
• 29. Saleem K, Khursheed Z, Hano C, Anjum I, Anjum S. Applications of nanomaterials in leishmaniasis: a focus on recent advances and challenges. MDPI AG 9(12), 1749 (2019).
  CASGoogle Scholar
• 30. Kar N, Chakraborty S, De AK, Ghosh S, Bera T. Development and evaluation of a cedrol-loaded nanostructured lipid carrier system for in vitro and in vivo susceptibilities of wild and drug resistant Leishmania donovani amastigotes. Eur. J. Pharm. Sci. 104, 196–211 (2017).
  Medline CASGoogle Scholar
• 31. Das S, Ghosh S, De AK, Bera T. Oral delivery of ursolic acid-loaded nanostructured lipid carrier coated with chitosan oligosaccharides: development, characterization, in vitro and in vivo assessment for the therapy of leishmaniasis. Int. J. Biol. Macromol. 102, 996–1008 (2017).
  Medline CASGoogle Scholar
• 32. Dahan A, Hoffman A. Evaluation of a chylomicron flow blocking approach to investigate the intestinal lymphatic transport of lipophilic drugs. Eur. J. Pharm. Sci. 24(4), 381–388 (2005).
  Medline CASGoogle Scholar
• 33. Borén J, Rustaeus S, Olofsson SO. Studies on the assembly of apolipoprotein B-100- and B-48-containing very low density lipoproteins in McA-RH7777 cells. J. Biol. Chem. 269(41), 25879–25888 (1994).
  Medline CASGoogle Scholar
• 34. Fan Z, Wu J, Fang X, Sha X. A new function of vitamin E-TPGS in the intestinal lymphatic transport of lipophilic drugs: enhancing the secretion of chylomicrons. Int. J. Pharm. 445(1–2), 141–147 (2013).
  Medline CASGoogle Scholar
• 35. Xu Q, Zhou A, Wu H, Bi Y. Development and in vivo evaluation of baicalin-loaded W/O nanoemulsion for lymphatic absorption. Pharm. Dev. Technol. 24(9), 1155–1163 (2019).
  Medline CASGoogle Scholar